After an Autism Diagnosis: Expert Guidance From Acorn Health
April marks Autism Acceptance Month, prompting families to confront new autism diagnoses. Acorn Health’s executive vice president Krista Orellana outlines five practical steps for parents, from emotional processing to securing insurance‑covered services. The guidance emphasizes early, evidence‑based ABA therapy as a pathway to communication and life‑skill development. With one in 31 U.S. children diagnosed, Acorn’s nationwide network aims to streamline access to specialized care.
Agenus Announces Data From Phase II Study of BOT+BAL in Combination with Agent-797 in PD-1 Refractory Gastroesophageal Cancer to Be...
Agenus announced that data from an investigator‑initiated Phase II trial of its multi‑mechanistic immunotherapy combo—botensilimab (BOT), balstilimab (BAL) and the allogeneic iNKT cell therapy agenT‑797—will be presented at the AACR Annual Meeting in April 2026. The study targets patients with PD‑1‑refractory gastroesophageal...
Innate Pharma to Participate in the Kempen Life Sciences Conference
Innate Pharma announced that senior executives will hold one‑on‑one investor meetings at the Kempen Life Sciences Conference in Amsterdam on April 15‑16, 2026. The biotech firm will use the event to showcase its pipeline, including the Nectin‑4 ADC IPH4502, the...
Vedanta Biosciences Announces the Phase 3 RESTORATiVE303 Study of VE303 for the Prevention of Recurrent C. Difficile Infection Will Continue...
Vedanta Biosciences announced that the independent Data Monitoring Committee has completed the first prespecified interim analysis of its Phase 3 RESTORATiVE303 trial and recommended the study continue unchanged. The interim data showed efficacy surpassing the futility threshold with no new safety...
Pulse Biosciences to Present at the 25th Annual Needham Virtual Healthcare Conference
Pulse Biosciences (Nasdaq: PLSE) will present at the 25th Annual Needham Virtual Healthcare Conference on April 16, 2026, at 9:30 am ET. The company will showcase its proprietary nPulse™ platform, which uses nanosecond pulsed field ablation (nsPFA™) to treat atrial fibrillation and...
Tandem Diabetes Care to Announce First Quarter 2026 Financial Results on May 7, 2026
Tandem Diabetes Care (Nasdaq: TNDM) will release its first‑quarter 2026 financial results on May 7, 2026, after the market closes. A conference call and live webcast will begin at 4:30 pm Eastern Time, with a 30‑day archived replay on the investor website. The...
CONMED Corporation to Announce First Quarter 2026 Financial Results on April 29, 2026
CONMED Corporation (NYSE: CNMD) announced it will report its first‑quarter 2026 financial results after the market close on Wednesday, April 29, 2026. Management will host a conference call at 4:30 p.m. ET the same day, with a live webcast and a...
SV Health Investors Acquires EpiVax
SV Health Investors (SVHI) announced the acquisition of EpiVax, a Providence‑based bioanalytical CRO that specializes in immunogenicity risk assessments for pharma and biotech firms. The deal adds a proven scientific platform, including the ISPRI predictive software and cell‑based assays, to...
Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of...
Vertex Pharmaceuticals announced that the U.S. FDA has approved label expansions for its CFTR modulators ALYFTREK and TRIKAFTA. ALYFTREK is now indicated for patients six years and older whose CFTR gene produces any functional protein, while TRIKAFTA’s indication now includes...
Zai Lab Announces Global Clinical Trial Collaboration and Supply Agreement to Evaluate Novel DLL3 ADC, Zocilurtatug Pelitecan, in Combination with...
Zai Lab and Amgen have entered a global collaboration to test Zai Lab’s DLL3‑targeting antibody‑drug conjugate, zocilurtatug pelitecan (zoci), together with Amgen’s FDA‑approved bispecific T‑cell engager IMDELLTRA® in extensive‑stage small cell lung cancer (ES‑SCLC). Amgen will sponsor and lead a...
Cyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement
Cyclerion Therapeutics and privately‑held Korsana Biosciences have signed an all‑stock merger agreement, creating a combined company that will operate as Korsana Biosciences and trade on Nasdaq under the ticker KRSA. Korsana secured an oversubscribed $380 million private placement that will fund...
Amprion Grows Global Footprint with Australian Partnership & Expanded Research Collaborations
Amprion announced a strategic partnership with Macquarie University to launch Australia’s first clinical alpha‑synuclein seed amplification testing site, expanding its global footprint. The company will continue collaborative research with the Michael J. Fox Foundation in 2026, integrating its SAAmplify‑ɑSYN assay into...
Novocure to Report First Quarter 2026 Financial Results
Novocure (NASDAQ: NVCR) announced it will disclose its first‑quarter 2026 financial results on April 30, 2026, before U.S. markets open. Management will host a conference call at 8:00 a.m. EDT, accompanied by a live webcast and slide deck available on the investor‑relations...
Bruker Announces Appointment of Thierry Bernard to Its Board of Directors
Bruker Corporation announced that Thierry L. Bernard has been appointed to its Board of Directors, effective immediately. Bernard, currently chief executive of QIAGEN, will step down after a successor is named. He brings decades of leadership in life‑science tools and diagnostics,...
CellCentric Initiates DOMMINO-1, a Pivotal Phase 2 Clinical Trial of Inobrodib in Combination with Pomalidomide and Dexamethasone (InoPd) in Relapsed...
CellCentric has launched the pivotal Phase 2 DOMMINO‑1 trial of inobrodib 20 mg combined with pomalidomide and dexamethasone (InoPd) in heavily pretreated relapsed or refractory multiple myeloma (RRMM) patients. The first dose was administered at The Royal Marsden in London, with additional...
ImmunityBio Strengthens Balance Sheet with $100 Million of Financing Transactions Including $75 Million of Non-Dilutive Financing to Support Global Expansion...
ImmunityBio secured $75 million of non‑dilutive financing under its existing royalty‑interest purchase agreement with Oberland Capital, raising total committed capital to $375 million. At the same time, Nant Capital converted $25 million of debt into common stock, reducing the company’s liabilities. The combined...
CapVest Completes Majority Acquisition of Stada
CapVest Partners LLP has completed the acquisition of a majority stake in Germany’s STADA Arzneimittel AG, a leading consumer‑health, generics and specialty pharma group. The deal follows STADA’s record 2025 performance, with revenue of €4.3 billion (approximately $4.73 billion) and adjusted EBITDA of €961 million...
AN2 Therapeutics Announces Initiation of Phase 2 Investigator-Initiated Clinical Trial of Epetraborole for Mycobacterium Abscessus Complex Lung Disease
AN2 Therapeutics has begun a Phase 2 investigator‑initiated trial of epetraborole, an oral leucyl‑tRNA synthetase inhibitor, for pulmonary disease caused by Mycobacterium abscessus. The randomized, double‑blind study will enroll 84 patients across roughly 10‑15 U.S. sites and is led by Dr. Kevin...
AI Med Consult and 4D EMR Announce Strategic Partnership to Advance AI-Driven Patient Engagement and Practice Efficiency
AI Med Consult and 4th Dimension EMR announced a strategic partnership at the AACS Annual Scientific Meeting, integrating AI‑driven patient engagement tools with 4D EMR’s aesthetic‑medicine platform. The combined solution will feed real‑time interaction data into electronic medical records, delivering...
Bristol Myers Squibb Evolves and Expands Standing in the Gaap to Advance More Equitable Care in Multiple Myeloma as Program...
Bristol Myers Squibb announced the evolution of its Standing in the Gaap program, expanding its reach to address equity gaps in multiple myeloma care. The initiative will launch one of the largest U.S. multiple myeloma surveys, targeting more than 1,000...
SignateraTM MRD Identifies Breast Cancer Patients Who Can Forgo Surgery
Natera’s Signatera circulating‑tumor DNA test was shown in a prospective Clinical Cancer Research study to identify older women (≥70) with early‑stage ER⁺/HER2‑ breast cancer who can safely forgo surgery and remain progression‑free on primary endocrine therapy. Baseline MRD‑negative patients (68%...
Canopy Growth’s Apollo Cannabis Clinics Named Best Medical Cannabis Clinic
Canopy Growth’s Apollo Cannabis Clinics was voted Best Medical Cannabis Clinic in the 2025 Toronto Star Readers’ Choice Awards, reflecting strong patient trust. The accolade spotlights Apollo’s free, fully virtual consultations that serve Canadians with personalized, evidence‑based treatment for chronic...
Sol-Millennium Medical Inc. Launches U.S. B2B eShop, Providing Direct Access to Safety Engineered Medical Devices Nationwide
Sol‑Millennium Medical Inc. has launched a dedicated U.S. B2B e‑commerce platform, b2b.solm.com, allowing healthcare providers nationwide to purchase its safety‑engineered medical devices directly. The site streamlines registration, pricing visibility, and order placement for settings ranging from physician offices to veterinary...
Bausch + Lomb Will Release First-Quarter 2026 Financial Results on April 29
Bausch + Lomb Corp. announced that it will publish its first‑quarter 2026 financial results on April 29, with a live investor conference call at 8 a.m. ET. The webcast and dial‑in details are provided, and a replay will be accessible through...
Prilenia and Ferrer Announce First Participant Enrolled in the “PREVAiLS” Phase 3 Study of Pridopidine in ALS
Prilenia Therapeutics and Ferrer have enrolled the first participant in PREVAiLS, a pivotal Phase 3, 500‑patient, randomized, placebo‑controlled trial of the sigma‑1 receptor agonist pridopidine for rapidly progressive ALS. The study, launched at Mass General Brigham, will span 48 weeks with...
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform
Meiji Seika Pharma announced a strategic investment in U.S. biotech Centivax to accelerate its universal influenza vaccine, Centi‑Flu 01, currently in Phase 1 trials. The partnership leverages Meiji’s pharmaceutical expertise and Centivax’s computational immune‑engineering platform to target conserved viral regions, aiming for...
Biocytogen Grants Taisho Pharmaceutical a License to Its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform
Biocytogen has licensed its RenNano® fully human heavy‑chain‑only antibody discovery platform to Japan’s Taisho Pharmaceutical, granting access to RenNano mice for in‑vivo generation and screening of VHH candidates. The agreement, whose financial terms remain undisclosed, adds to Biocytogen’s expanding portfolio...
Advanced eClinical Training Partners with Emory University’s HeartStart Program to Deliver Medical Assistant Training for Pre-Medical Students
Advanced eClinical Training (ACT) has partnered with Emory University’s HeartStart program to launch a customized Clinical Medical Assistant (CCMA) training pathway for pre‑medical students. The inaugural cohort will include 50 learners who will receive certification preparation, simulation‑based patient‑care training, and...
Springfield Facility Expansion Marks Key Growth Milestone for Alltrista
Alltrista Plastics, a Jadex Inc. subsidiary, announced a 25,000‑square‑foot expansion of its Springfield, Missouri plant, slated for completion in September 2026. The multimillion‑dollar project will add new jobs and increase output for its medical and consumer packaging lines. The upgraded...
LiftWell Health Announces Brand Consolidation, Board & Presidential Appointment, In-Network Expansion, and Strategic Advisory Board
LiftWell Health merged Lift Wellness Group and LiftWell under a single brand, unveiling a new website to present a unified clinical vision across Connecticut and the broader Northeast. The organization appointed Awstin Gregg, MBA, LCSW‑S, LCDC, as President and Board...
New Nature-Published Research Reviews How Metabolic Dysfunction May Be Core Driver in Psychiatric Diseases
A new review in Nature Mental Health, led by Stanford’s Dr. Shebani Sethi, consolidates evidence from 138 studies that metabolic dysfunction is a central driver of schizophrenia, bipolar disorder, and major depression. The paper argues that impaired energy metabolism, not...
Kardigan Announces Positive Phase 2 Data for Tonlamarsen in Patients with Uncontrolled Hypertension Presented as Late-Breaker at ACC.26 and Simultaneously...
Kardigan reported positive Phase 2 data for its antisense drug tonlamarsen in the KARDINAL trial, showing a dose‑dependent 67% reduction in plasma angiotensinogen and a mean 6.7 mmHg drop in office systolic blood pressure after 20 weeks. Both a single 90 mg dose...
Arrowhead Pharmaceuticals Presents New Long-Term Efficacy and Safety Data for Plozasiran Across a Spectrum of Hypertriglyceridemia at the American College...
Arrowhead Pharmaceuticals presented two‑year open‑label extension data for plozasiran at the ACC 75th session, showing an 83% median triglyceride reduction in severe hypertriglyceridemia and 96% of patients dropping below the 500 mg/dL pancreatitis threshold. No adjudicated acute pancreatitis events occurred, and...
Open Label Outpatient Switch Study Demonstrates Symptom Stability During Transition From Oral Atypical Antipsychotics to Cobenfy™ (Xanomeline and Trospium Chloride)
Bristol Myers Squibb reported Phase 4 data showing that adults with schizophrenia can switch from oral atypical antipsychotics to Cobenfy (xanomeline‑trospium) without loss of symptom control. In an 8‑week open‑label trial, 86% of 105 patients completed the study, and mean PANSS...
IVF Academy USA Launches Accelerated Program to Help OBGYNs Bring Fertility Services Into Their Practices
IVF Academy USA unveiled a 30‑hour hybrid OBGYN Clinic‑Ready Fertility Services Accelerator, blending 14 hours of online coursework with a two‑day hands‑on residency. The program equips board‑certified OBGYNs to deliver in‑office fertility evaluations, IUI, and diagnostic hysteroscopy, complete with billing...
Banner|Aetna Brings Community Together for 2026 Phoenix Heart Walk
Banner | Aetna, the Arizona health‑plan joint venture of Banner Health and Aetna, is participating in the 2026 Phoenix Heart Walk as a member of the event’s Executive Leadership Team. CFO Dan Keller volunteers his time, highlighting a personal connection to heart...
Mochi Health and Livelong Women’s Health Summit Partner to Advance Women’s Metabolic Health
Mochi Health announced its role as a Premiere Sponsor of the Livelong Women’s Health Summit, scheduled for April 17‑18 in San Francisco. Founder and CEO Myra Ahmad, M.D., will headline a session on GLP‑1 medications and host a roundtable on...
LEO Pharma Announces New Long-Term Data for SPEVIGO® (Spesolimab-Sbzo) Injection in Adults with Generalized Pustular Psoriasis at AAD 2026
LEO Pharma presented long‑term results from the five‑year EFFISAYIL ON extension, showing subcutaneous SPEVIGO® reduced generalized pustular psoriasis (GPP) flares from an average of two per year to 0.13, with 74.6% of patients experiencing no flares over three years. Intravenous SPEVIGO...
VIVAZEN® Urges Immediate Action on 7-OH as U.S. House of Representatives Examines End Needless Distribution of 7-OH Act
VIVAZEN® welcomed a House Energy and Commerce subcommittee hearing on H.R. 8000, the End Needless Distribution of 7‑OH Act, urging the DEA to promptly schedule the synthetic opioid 7‑hydroxymitragynine. The company highlighted public‑health risks such as toxicity, dependence and market confusion...
FranklinCovey Provides Customized Solutions for Healthcare Organizations to Solve Key Issues: Nurse Retention and Patient Satisfaction
FranklinCovey is teaming with hospital leaders to boost nurse retention and patient satisfaction through customized leadership and trust programs. Documented results include moving patient‑satisfaction percentiles from the 26th to the 76th in four months and cutting leadership turnover by half...
Agenus to Host March 2026 Stakeholder Webcast Harnessing the Immune System to Advance BOT + BAL Across Tumor Types and...
Agenus announced a March 31, 2026 stakeholder webcast to detail progress on its botensilimab and balstilimab (BOT + BAL) immunotherapy program. The company highlighted clinical durability across multiple tumor types, with roughly 1,200 patients treated with botensilimab and over 900 with balstilimab...
Pediatrix Expands Maternal Health Services in Tennessee in Partnership with Tennessee Maternal-Fetal Medicine
Pediatrix Medical Group announced a cash acquisition of Tennessee Maternal‑Fetal Medicine, adding four board‑certified MFM physicians and six advanced practice providers to its Nashville operations. The partnership expands Pediatrix’s presence to five Greater Nashville locations, enhancing access to high‑risk obstetric...
Alpha Cognition Inc. Reports Fiscal 2025 Financial Results and Provides Operational Update
Alpha Cognition reported fourth‑quarter 2025 revenue of $2.5 million from its Alzheimer’s drug ZUNVEYL, bringing full‑year revenue to about $10.2 million. The company added a second national PBM contract, expanding coverage to two of the four major long‑term‑care payers, and saw prescriber...
GetHealthy Launches Script, an AI-Enabled Platform Expanding Practitioner Commerce Beyond Supplements Across Seven Product Categories
GetHealthy unveiled Script, an AI‑enabled clinical scripting platform that lets health practitioners prescribe comprehensive protocols across seven product categories, from supplements to pet health and diagnostic testing. The solution taps a catalog of over 400 vetted brands and integrates with...
AI-Powered Virtual Oncology Gets Smarter: Reimagine Care Advances Remi to Capture the Nuance of Cancer Patient Conversations
Reimagine Care announced a major upgrade to its AI‑powered virtual oncology assistant, Remi, shifting from rule‑based scripts to natural‑language understanding that can interpret complex patient messages. The SMS‑based platform now adds safety guardrails, AI‑assisted clinician summaries, and expanded monitoring for...
U.S. FDA Approves Label Update to Accelerate Thaw Time for ADSTILADRIN® (Nadofaragene Firadenovec-Vncg)
The U.S. FDA has approved a label update for Ferring Pharmaceuticals' ADSTILADRIN® (nadofaragene firadenovec‑vncg) that permits an accelerated water‑bath thawing process completed in roughly 25 minutes. The therapy, the only FDA‑approved non‑replicating intravesical gene‑therapy for high‑risk BCG‑unresponsive non‑muscle invasive bladder...
Phreesia Named One of Becker’s Top Places to Work in Healthcare
Phreesia has been named one of Becker’s Healthcare Top Places to Work for 2026, marking its second appearance on the prestigious list. The accolade recognizes the company’s fully remote structure, competitive compensation, flexible time off, home‑office support, generous parental benefits...
Mark Farrah Associates’ Health Coverage Portal Simplifies Health Insurance Data Analytics
Mark Farrah Associates (MFA) has released its 2025 health‑plan data through the Health Coverage Portal™. The portal aggregates statutory financial statements from the NAIC and California DMHC, offering enrollment, market‑share, revenue, expense, and loss‑ratio metrics for individual, group, ASO and...
Impact Podcast with John Shegerian Features Special Two-Part, In-Depth Interview with Dr. Dawn Mussallem
Dr. Dawn Mussallem, newly appointed chief medical officer of longevity firm Fountain Life, appears in a two‑part interview on the Impact Podcast with John Shegerian. The episode highlights her personal survival story—from a stage IV cancer diagnosis and a 2021 heart...
Prestige Medical Group Announces New Woodstock Location, Expanding Access to Care in Cherokee County
Prestige Medical Group, a physician‑led network serving North Georgia for over two decades, opened a new office in Woodstock, Georgia on March 24, 2026. The 102 Springfield Center Drive clinic provides primary care and pediatric services five days a week and also...